Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
July 25, 2019 07:00 ET
|
Capricor Therapeutics, Inc.
--Independent Data Safety Monitoring Board recommends to continue HOPE-2 study-- --Capricor to resume treating currently enrolled patients-- LOS ANGELES, July 25, 2019 (GLOBE NEWSWIRE) -- Capricor...
Title21 Health Solutions Is a ‘Great Place to Work’®
February 01, 2019 11:40 ET
|
Title21 Health Solutions, Inc.
Cellular Therapy and Enterprise Quality Management Software Company is Recognized as Having an Outstanding Culture by Great Place to Work® PLEASANTON, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) --...
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
November 09, 2018 08:00 ET
|
Nkarta
NK cell potency and persistence significantly improved using cell engineering technology60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cellsSingle in vivo...
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
November 06, 2018 08:01 ET
|
Sorrento Therapeutics, Inc.
Two out of four patients showed complete resolution of liver metastases on PET scanMedian overall survival (OS) 8.3 months and mean OS 9.8 months, compared to the standard of care 3 to 6 monthsMeeting...
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
November 01, 2018 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to...
BioBridge Global to highlight capabilities in regenerative medicine at AABB Annual Meeting
October 12, 2018 12:48 ET
|
BioBridge Global
San Antonio, Oct. 12, 2018 (GLOBE NEWSWIRE) -- BioBridge Global will be showcasing its regenerative medicine capabilities at the AABB Annual Meeting in Boston, including the ability to provide human...
Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
July 17, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 17, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to...
Nkarta Therapeutics Announces Exclusive License to Natural Killer Cell Technology From National University of Singapore and St. Jude Children’s Research Hospital
June 11, 2018 08:00 ET
|
Nkarta
SOUTH SAN FRANCISCO, Calif., June 11, 2018 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held cell therapy company developing Natural Killer (NK) immune cells to fight cancer, today announced...
Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
April 30, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 30, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) today announced it has initiated the HOPE-2 clinical trial at UC Davis Medical Center. The trial will test...
Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
April 19, 2018 07:00 ET
|
Capricor Therapeutics, Inc.
LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced that researchers found that repeat dosing of the company’s proprietary cellular therapy yields an...